BioKeralty Research Institute is part of Keralty group’s research, development and innovation (R&D&I) division. Following the Keralty’s health model principles, BioKeralty drives and coordinates research and development projects in several health areas. The main research areas are: chronic diseases, regenerative medicine, cancer, personalized medicine or digital health, as well as health value, social care and community care.
Thought its participation in several partnerships, R&D&I projects and related calls, Keralty group works in the implementation of attention models, management models and health technologies and tools. In this way, Keralty aims to create competitive advantage that will allow the group share and add value to its patients and health professionals.
CARAMEL is pleased to announce the launch of a large-scale study aimed at assessing cardiovascular risk factors in women aged 40 to 60, particularly during the menopausal transition. The study, involving leading research and clinical partners across Europe and Latin America – including Trinity College Dublin,…
More than 500 Keralty executives, physicians and healthcare staff, together with Joseba Grajales, President of the group, and his launch team, gathered in Bogota on 19 March to learn about and support a historic initiative that will position the group as one…
For those people interested in the scientific publications and patents developed by the BioKeralty team, this section gathers detailed information and useful references corresponding to its scientific research.
Nanomaterials, biomedical applications, in vitro and in vivo antimicrobial activities, nanomedicine, fatty acids, nanofibrous membranes, tissue reparations, etc. constitute some of the research topics included in this section.
Primary care
Cancer
Chronic and neurodegenerative
Infectious diseases
E-health
Genomics and personalized
Regenerative medicine
Nanotechnology
Education
Community
Social
Health value